{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-000398","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2026-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.183981+00:00","generated_at":"2026-05-16T09:35:40.309827+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"Tivic Health releases corporate presentation highlighting late-stage pipeline in radiation damage and oncology","bullets":["Company targeting multiple high-value inflection points expected within the next 18-24 months.","Focus on competitively differentiated treatments for radiation damage, oncology, and immune system modification.","Pipeline described as late-stage and highly de-risked; experienced management team in place.","Corporate presentation furnished as Exhibit 99.1; no specific financial or clinical data disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-000398","json":"https://secwatch.observer/filing/0001683168-26-000398.json","markdown":"https://secwatch.observer/filing/0001683168-26-000398.md","text":"https://secwatch.observer/filing/0001683168-26-000398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826000398/0001683168-26-000398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826000398/tivic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:35:40.309827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}